Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6060052

Title:Methods for use of Mpl ligands with primitive human hematopoietic stem cells
Inventors:Murray, Lesley J.; San Jose, CA, USA
Young, Judy C.; San Carlos, CA, USA
Summary:Described herein are myeloproliferative leukemia receptor (mpl) ligands and methods of their use. The invention relates to mpl ligands such as thrombopoietin which are described herein as acting on a primitive subpopulation of human stem cells having the characteristics of self-renewal and the ability to give rise to all hematopoietic cell lineages. Claims of the invention include support by thrombopoietin of both megakaryocytic differentiation and primitive progenitor cell expansion of the CD34+ and CD34+ sub-populations (CD34+ Lin-, CD34+ Thy-1+ Lin-, and CD34+ Lin- Rh123lo). Thrombopoietin is further described herein as stimulating quiescent human stem cells to begin cycling. Therapeutic applications include the stimulation of stem cells for the restoration of hematopoietic capability, and applications in gene therapy.
Abstract:Myeloproliferative leukemia receptor (mpl) ligands, such as thrombopoietin, act on a primitive subpopulation of human stem cells having the characteristics of self-renewal and ability to give rise to all hematopoietic cell lineages. Thrombopoietin supports both megakaryocytic differentiation and primitive progenitor cell expansion of CD34.sup.+ and CD34.sup.+ sub-populations (CD34.sup.+ Lin.sup.-, CD34.sup.+ Thy-1.sup.+ Lin.sup.-, and CD34.sup.+ Lin.sup.- Rh123.sup.lo). Thrombopoietin also stimulated quiescent human stem cells to begin cycling. Thus, mpl ligands are useful for expanding primitive stem cells for restoration of hematopoietic capabilities and for providing modified human stem cells for gene therapy applications.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6060052
Application Number:US1995000550167
Date Filed:30/10/1995
Date Published:09/05/2000
Assignee:SyStemix, Inc., Palo Alto, CA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/23/2021